Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Respiratory SystemDRG 196-interstitial-lung-disease-with-mcc
    Ask Trek AI about this page

    Interstitial Lung Disease with MCC: Inpatient Reimbursement Overview

    DRG 196 designates inpatient stays for interstitial lung disease with a Major Complication or Comorbidity, reflecting higher clinical complexity and resource needs. This matters for inpatient reimbursement because the Major Complication or Comorbidity status increases the Diagnosis-Related Group weight, influencing Medicare payments for the admission.

    Customize your policy alerts

    Sign up for drg 196 policy alerts

    Get alerted when payer policies referencing 196 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 196 Overview

    DRG 196 covers hospital admissions for interstitial lung disease with a Major Complication or Comorbidity. This category captures complex cases where severe respiratory dysfunction or related organ involvement increases resource use. It is important for Medicare payment because the presence of a Major Complication or Comorbidity raises the relative weight and reimbursable resources for inpatient care. Accurate clinical documentation and coding determine assignment to this higher-severity Diagnosis-Related Group and affect hospital reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute inpatient management trials focusing on ventilatory and immunomodulatory strategies for hospitalized patients with interstitial lung disease (ILD) experiencing respiratory failure or acute exacerbation. These studies enroll patients admitted with severe hypoxemia, often requiring supplemental oxygen, high-flow nasal cannula, noninvasive ventilation, or mechanical ventilation, and compare different approaches (timing and intensity of respiratory support, corticosteroid regimens, or adjunctive immunosuppressive therapy) to determine short-term clinical outcomes such as in-hospital mortality, need for ICU-level care, and duration of mechanical ventilation. Results inform hospital clinical pathways and resource allocation decisions relevant to payers tracking cost and utilization for this high-acuity DRG.
    • Comparative effectiveness studies in the inpatient-to-early-postdischarge period evaluating antifibrotic agents, maintenance immunomodulation, or rehabilitation strategies to reduce readmissions and slow disease progression. These studies typically enroll patients hospitalized for ILD complications to compare alternative medication strategies, combination therapies, or initiation timing, and measure outcomes like 30- and 90-day readmission rates, functional status at discharge, and progression on pulmonary function testing. Findings are directly relevant for clinicians deciding in-hospital treatment plans and for payers concerned with downstream costs, readmission penalties, and long-term disease trajectory after a costly hospitalization.
    • Observational and outcomes research assessing care pathways, comorbidity management, and palliative care integration for complex ILD patients with major complications (MCC) to understand drivers of length of stay, discharge disposition, and end-of-life care. These cohort and registry studies examine heterogeneous inpatients with advanced fibrotic ILD, connective tissue–associated ILD, or drug-related pneumonitis, analyzing how comorbid heart failure, pulmonary hypertension, or infection impact resource use, mortality, and quality-of-life measures. Such evidence helps providers optimize multidisciplinary inpatient care coordination and enables payers to identify high-cost subgroups, target case management, and design bundled payment or value-based programs for this DRG.

    Related Codes

    163-MAJOR-CHEST-PROCEDURES-WITH-MCC

    Major Chest Procedures with MCC: Inpatient Reimbursement Overview

    164-MAJOR-CHEST-PROCEDURES-WITH-CC

    Major Chest Procedures with CC: Inpatient Reimbursement Overview

    165-MAJOR-CHEST-PROCEDURES-WITHOUT-CC-MCC

    Major Chest Procedures without CC/MCC: Inpatient Reimbursement Overview

    166-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITH-MCC

    Other Respiratory System O.R. Procedures with MCC: Inpatient Reimbursement Overview

    167-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITH-CC

    Other Respiratory System O.R. Procedures with CC: Inpatient Reimbursement Overview

    168-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITHOUT-CC-MCC

    Other Respiratory System O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    173-ULTRASOUND-ACCELERATED-AND-OTHER-THROMBOLYSIS-WITH-PRINCIPAL-DIAGNOSIS-PULMONARY-EMBOLISM

    Ultrasound Accelerated and Other Thrombolysis with Principal Diagnosis Pulmonary Embolism: Inpatient Reimbursement Overview

    175-PULMONARY-EMBOLISM-WITH-MCC-OR-ACUTE-COR-PULMONALE

    Pulmonary Embolism with MCC or Acute Cor Pulmonale: Inpatient Reimbursement Overview

    176-PULMONARY-EMBOLISM-WITHOUT-MCC

    Pulmonary Embolism without MCC: Inpatient Reimbursement Overview

    177-RESPIRATORY-INFECTIONS-AND-INFLAMMATIONS-WITH-MCC

    Respiratory Infections and Inflammations with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 40

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.